2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

621. Lymphomas: Translational: Molecular and Genetic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1735 Current prognostic indices are unable to identify cured populations with FL: Comparison of three follicular lymphoma prognostic scoring systems in SWOG S0016 with long-term follow-up

Swetha Thiruvengadam, MD, Hongli Li, MS2, Michael Leblanc, MD3, Colleen Ramsower, MS, MB4, Jennifer E. Amengual, MD5, Jonathan W. Friedberg, MD6, Gabby Lopez, MS7, Mazyar Shadman, MD, MPH8, Sonali Smith, MD, FASCO9, Lisa Rimsza, MD, PhD10
1 City of Hope National Medical Center, Duarte, United States
2 Fred Hutch Cancer Center, Seattle, United States
3 Fred Hutch Cancer Center, Seattle, United States
4 University of Arizona, Tuscon, United States
5 Columbia University, New York, United States
6 University of Rochester, Rochester, United States
7 University of Arizona, Tuscon, United States
8 Fred Hutch Cancer Center, Seattle, United States
9 University of Chicago, Chicago, United States
10 University of Arizona, Tuscon, United States

S0016, a phase III study of CHOP-R vs CHOP-RIT for patients (pts) with advanced-stage FL, demonstrated 15-year OS 70% and 15-year PFS 40%, with a subset of pts that can be cured. Identifying which pts will achieve cure is an important objective of prognostic tools.  The m7-FLIPI integrates the mutation status of 7 genes, ECOG, and clinical factors in FLIPI, but its prognostic value may depend on the treatment. Other prognostic tools in FL include FLIPI and FL24Cx, a 45-target gene expression profiling assay validated to predict early progression in immunochemotherapy-treated pts. Prior analysis from S0016 demonstrated that LDH, β2M, and FLIPI scores significantly correlated with outcome, but histological grades did not. The goal of this analysis from S0016 is to correlate m7-FLIPI risk with long-term outcomes and compare the results with FLIPI and FL24Cx.

DNA was isolated from pre-treatment FFPE tissues and sent for whole-exome sequencing, processed with MuTect2 for somatic mutation calling (tumor-only), and underwent post-processing filtering of non-silent mutations with a minimum allele frequency of 10% and a read depth of 20. There were 121 analyzable cases for m7-FLIPI and 106 analyzable for FL24Cx. Survival endpoints were defined from the time of randomization. PFS was defined as first observation of progression or death due to any cause. POD24 was defined as disease progression, relapse, or death due to FL within 2 years of randomization. OS was defined as death from any cause. K-M analysis was performed to investigate the prognostic significance of high vs low risk m7-FLIPI with PFS and OS. HR were calculated from the Cox proportional hazards model. The Fisher exact test was applied to compare the difference in distribution of early progressors among pts with or without high risk m7-FLIPI.

In the m7-FLIPI analysis cohort, median age was 55y (range, 28-80y), 28 (23%) had B symptoms, 22 (18%) had bulky (>10 cm) disease, 57 (47%) had bone marrow involvement, and 117 (97%) had advanced stage. FLIPI risk was low in 35 (29%), intermediate in 52 (43%), high in 34 (28%). The majority of pts, 106 (88%), had m7-FLIPI low risk, and 15 (12%) had m7-FLIPI high risk. Baseline clinical characteristics were comparable between the low and high risk m7-FLIPI cohorts. All pts in the high-risk m7 FLIPI cohort had high FLIPI risk; in the low risk m7-FLIPI cohort, 35 (33%) had low FLIPI risk, 52 (49%) had intermediate FLIPI risk, and 19 (18%) had high FLIPI risk. In terms of treatment, 48 (45%) and 58 (55%) of the low-risk cohort were treated with CHOP-R and CHOP-RIT respectively and 5 (33%) and 10 (67%) of high risk cohort were treated with CHOP-R and CHOP-RIT respectively.

PFS at 15 years when stratified by the 3 prognostic tools was 17% (3% - 40%) vs 42% (32% - 52%) for m7-FLIPI high vs low risk (HR 2.18, p= 0.012); 22% (9% - 38%) vs 46% (34% - 56%) for FLIPI high vs low /intermediate risk (HR 2.26, p= 0.0007); 21% (7%-39%) vs 45% (33%-57%) for FL24Cx high vs low risk (HR 1.95, p=0.02). When the m7FLIPI risk was applied to the 34 pts with high-risk FLIPI, there was no further stratification with 15-yr PFS 17% (3% - 40%) vs 25% (8% - 48%) (HR 1.16, p=0.72) for high vs low risk.

The relative risk of POD24 for m7-FLIPI high vs low risk was 2.1 [95% CI (1.00-4.38), p=0.09] and for FL24Cx high vs low risk was 2.47 [95% CI (1.21-5.04), p=0.02].

OS at 15 years when stratified by the 3 prognostic tools was 51% (24% - 73%) vs 79% (69% - 86%) for m7-FLIPI high vs low risk (HR 2.31, p= 0.0429); 54% (36% - 69%) vs 84% (73% - 90%) for FLIPI high vs low/intermediate risk (HR 3.05, p= 0.0006); 77% (54%-90%) vs 80% (69%-88%) for FL24Cx high vs low/intermediate risk with no statistically significant difference (HR 0.67 p = 0.42).

We recently demonstrated that a proportion of FL pts are cured after chemoimmunotherapy. The current analysis from S0016, with a median follow-up > 15y, evaluates established prognostic tools and demonstrates that m7-FLIPI, FLIPI, and FL24Cx all identify a high risk population, with high risk m7-FLIPI associated with a 2-fold inferior PFS and OS. However, the m7-FLIPI did not improve upon the prognostic capabilities of the FLIPI and did not identify a population that was cured. We acknowledge that small sample size in the m7-FLIPI high risk cohort is a limitation. There remains an unmet need to refine prognostic tools, perhaps incorporating ctDNA, to better risk stratify FL pts and predict progression, survival, and cure.

Swetha Thiruvengadam, MD: Innate Pharma SA - Honoraria; ADC Therapeutics - Research Funding; Genmab - Research Funding; Genentech - Research Funding; Innate Pharma SA - Consultancy (Includes expert testimony)